Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.23)
# 398
Out of 4,843 analysts
231
Total ratings
39.52%
Success rate
20.14%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $3.21 | +398.44% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $6.88 | +45.35% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $9.89 | +203.34% | 6 | May 14, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | $25 | $8.55 | +192.40% | 2 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $48.52 | +130.83% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $19.19 | +19.85% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $37.60 | +115.43% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.71 | +158.30% | 16 | Apr 28, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $67 → $123 | $73.35 | +67.69% | 6 | Mar 27, 2025 | |
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $90 | $3.40 | +2,547.06% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.15 | +225.58% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $46.68 | +182.78% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $19.84 | +26.01% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $34.03 | +246.75% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $31.70 | +13.56% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $19.78 | +238.73% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.07 | +245.96% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $9.84 | +194.72% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $2.71 | +527.31% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $0.85 | +841.40% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $14.47 | +300.83% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $2.30 | +378.26% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $6.24 | +188.69% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.98 | +607.07% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.67 | +386.89% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.54 | +1,263.64% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.66 | +802.66% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.84 | +986.96% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.97 | +674.41% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.31 | +68,602.29% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.53 | +7,616.92% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.07 | +12,929.32% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.77 | +10,938.96% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.98 | +2,478.80% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.31 | +3,335.11% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.84 | +1,215.63% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.56 | +3,746.15% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.09 | +8,156.88% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $1.43 | +176,123.78% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.49 | +32,553.06% | 1 | Jan 9, 2020 |
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $3.21
Upside: +398.44%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $6.88
Upside: +45.35%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $9.89
Upside: +203.34%
Zevra Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $25
Current: $8.55
Upside: +192.40%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $48.52
Upside: +130.83%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $19.19
Upside: +19.85%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $37.60
Upside: +115.43%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.71
Upside: +158.30%
Soleno Therapeutics
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $73.35
Upside: +67.69%
X4 Pharmaceuticals
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.40
Upside: +2,547.06%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.15
Upside: +225.58%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $46.68
Upside: +182.78%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.84
Upside: +26.01%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $34.03
Upside: +246.75%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $31.70
Upside: +13.56%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $19.78
Upside: +238.73%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.07
Upside: +245.96%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $9.84
Upside: +194.72%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $2.71
Upside: +527.31%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $0.85
Upside: +841.40%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.47
Upside: +300.83%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $2.30
Upside: +378.26%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $6.24
Upside: +188.69%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.98
Upside: +607.07%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.67
Upside: +386.89%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.54
Upside: +1,263.64%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.66
Upside: +802.66%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.84
Upside: +986.96%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.97
Upside: +674.41%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.31
Upside: +68,602.29%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.53
Upside: +7,616.92%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.07
Upside: +12,929.32%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.77
Upside: +10,938.96%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.98
Upside: +2,478.80%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.31
Upside: +3,335.11%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.84
Upside: +1,215.63%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.56
Upside: +3,746.15%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.09
Upside: +8,156.88%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $1.43
Upside: +176,123.78%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.49
Upside: +32,553.06%